Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
NewAmsterdam Pharma Company ( (NAMS) ) has shared an announcement.
On May 7, 2025, NewAmsterdam Pharma announced additional data from its BROADWAY and TANDEM Phase 3 clinical trials, presented at the European Atherosclerosis Society Congress and published in leading medical journals. The data demonstrated significant reductions in LDL-C levels and improvements in cardiovascular biomarkers with the use of obicetrapib, both as monotherapy and in combination with ezetimibe, highlighting its potential as a foundational therapy in CVD management. The trials showed a 45% reduction in lipoprotein(a) and a 21% reduction in major adverse cardiovascular events, reinforcing obicetrapib’s promise as an effective oral treatment for CVD.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
NewAmsterdam Pharma’s stock score is impacted by financial challenges typical of biotech firms, such as operational losses and negative cash flow. The strong balance sheet and strategic board appointment offer stability and future growth potential. However, weak technical indicators and valuation metrics underscore caution in the short term.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease (CVD) with elevated low-density lipoprotein cholesterol (LDL-C), particularly for those for whom existing therapies are not sufficiently effective or well-tolerated.
Average Trading Volume: 994,552
Technical Sentiment Signal: Sell
Current Market Cap: $2.13B
For detailed information about NAMS stock, go to TipRanks’ Stock Analysis page.